Inhibrxの時価総額
Inhibrxの時価総額は何ですか。
Inhibrx, Inc.の時価総額は1.28B$です。
時価総額の定義は何ですか。
時価総額は、取引された会社の発行済株式の市場価値であり、一定期間のb株式に発行済株式数を掛けたものに等しい。
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
NASDAQのセクタHealth Careにおける時価総額の企業と比べるInhibrx
Inhibrxは何をしますか。
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Inhibrxと類似の時価総額
- secunet Security Networks AGの時価総額は1.28B$です。
- China Water Affairsの時価総額は1.28B$です。
- ModivCareの時価総額は1.28B$です。
- Deutsche EuroShop AGの時価総額は1.28B$です。
- Akzo Nobel Indiaの時価総額は1.28B$です。
- Federal Home Loan Mortgageの時価総額は1.28B$です。
- Inhibrxの時価総額は1.28B$です。
- Cairn PLCの時価総額は1.28B$です。
- Bnp Paribas Easy Equity Dividenの時価総額は1.28B$です。
- The Fertilisers And Chemicals Travancoreの時価総額は1.28B$です。
- Loral Space & Communications Incの時価総額は1.28B$です。
- Live Oak Bancshares Incの時価総額は1.28B$です。
- Akzo Nobel Indiaの時価総額は1.28B$です。